Videos

Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.

In interim data, a redesigned biopsy needle produced longer, less fragmented prostate cores, according to James S. Wysock, MD.

Suzanne B. Merrill, MD, discusses emerging perioperative approaches in MIBC and the potential for more personalized treatment selection based on disease characteristics.

Benjamin Garmezy, MD, discusses personalizing mHSPC treatment intensification based on disease burden, molecular biomarkers, and patient-specific factors.

Tamim Niazi, MDCM, unpacks the interim DASL-HiCaP data, why conventional imaging was the chosen yardstick, and how to frame 96 weeks of therapy for patients.

William Huang, MD, discusses histotripsy for renal tumors, the #HOPE4KIDNEY trial, and the technology’s potential to preserve kidney function.

Alicia Morgans, MD, discusses ARACOG findings on cognitive outcomes with darolutamide vs enzalutamide and the influence of genetic dementia risk.

Elie Kaplan-Marans, MD, discusses geographic disparities in reproductive urology access and how workforce gaps may affect comprehensive infertility evaluations.

Perioperative durvalumab (Imfinzi) plus 3 cycles of neoadjuvant enfortumab vedotin-ejfv (Padcev) improved survival in cisplatin-ineligible muscle-invasive bladder cancer.

Aaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.

Paras H. Shah, MD, recaps data on emerging agents in high-risk NMIBC from the 2026 AUA North Central Section Meeting.

Tamim Niazi, MDCM, reviews DASL-HiCaP findings showing improved metastasis-free survival with darolutamide added to ADT and radiation therapy.

Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.

Roger Li, MD, addresses the open questions surrounding adjuvant therapy after cystectomy, the urologist's role in recognizing treatment-related toxicities, and why multidisciplinary referral is the change most likely to deliver the full benefit of perioperative therapy.

Roger Li, MD, explains why patients with MIBC fall away between TURBT and a medical oncology visit, how strong urologist–oncologist relationships speed the start of neoadjuvant therapy, and how newer non-cisplatin regimens are changing referral patterns and surgical timing.

Roger Li, MD, reviews how the NIAGARA, KEYNOTE-905, KEYNOTE-B15, and VOLGA trials are moving perioperative care for muscle-invasive bladder cancer beyond cisplatin-based chemotherapy and why the data should change which patients urologists refer for neoadjuvant therapy.

Chad Ritch, MD, discusses how PSMA-PET informs patient management across different stages of the prostate cancer journey.

Alicia K. Morgans, MD, MPH, reviews promising prostate cancer findings from ESMO 2026,

Explore how very high-risk localized prostate cancer is defined and treated, plus why PSMA PET findings shouldn’t automatically rule out curative therapy.

The 2026 LUGPA Annual Meeting will tackle policy, artificial intelligence, and practice growth, according to Benjamin H. Lowentritt, MD, FACS.

Alberto Briganti, MD, PhD, discusses results from the PROTEUS substudy, evaluating perioperative apalutamide plus ADT vs surgery alone in high-risk localized or locally advanced prostate cancer.

Andrea Necchi, MD, discusses how results from the CA017-078 trials compares with other perioperative immunotherapy trials in muscle-invasive bladder cancer.

Neoadjuvant-only enfortumab vedotin in VOLGA may spare neuropathy, according to Alexandra Drakaki, MD, PhD; Guru P. Sonpavde, MD, urged caution.

Carlos A. Vargas, MD, discusses updated survival outcomes, safety, and the mechanism of SYNC-T SV-102, an investigational in situ immunotherapy for metastatic prostate cancer.

Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.

Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.

Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.

Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.

Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.

Selecting candidates for radioligand therapy requires more than a positive PSMA scan, and the panel details how tracer avidity, disease volume, and sequencing with hormonal therapy affect outcomes.